Geode Capital Management
VBIO

Geode Capital Management’s Valion Bio VBIO Stock Holding History

Geode Capital Management’s Portfolio VBIO Stock Details VBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.1K Sell
775
-2,738
-78% -$59.6K ﹤0.01% 4422
2026
Q1 		$77.8K Buy
+3,513
New +$89.9K ﹤0.01% 4195
2025
Q1 		– Sell
-86
Closed -$12.4K – 4506
2024
Q4 		$12.4K Hold
86
– – ﹤0.01% 4425
2024
Q3 		$9.1K Sell
86
-1
-1% -$151 ﹤0.01% 4483
2024
Q2 		$14.3K Buy
87
+56
+181% +$17.6K ﹤0.01% 4509
2024
Q1 		$16K Buy
31
+4
+15% +$2.31K ﹤0.01% 4508
2023
Q4 		$20.6K Buy
+27
New +$19.4K ﹤0.01% 4510

Other funds holding VBIO

M
Murchinson Toronto, Ontario, Canada $725M AUM 82.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
SA
Sanctuary Advisors Indianapolis, Indiana $21.6B AUM 28.31% 1-Year Est. Return
MG
Marex Group London $23.6B AUM 57.16% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
TSS
Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

Geode Capital Management's VBIO Position: Q2 2026 in Review

Geode Capital Management reduced its Valion Bio (VBIO) stake by 78% in Q2 2026, selling an estimated $59.6K and leaving 775 shares worth $10.1K. The position accounts for ﹤0.01% of the portfolio, ranked #4422.

Geode Capital Management first reported a position in VBIO in Q4 2023 and has held it in 7 quarters since. The position peaked at $77.8K in Q1 2026. 11 funds tracked by Wall St. Rank hold VBIO as of Q2 2026.

  • Geode Capital Management held 775 shares of Valion Bio worth $10.1K as of Q2 2026.
  • Geode Capital Management sold 2,738 Valion Bio shares in Q2 2026, an estimated $59.6K.
  • Valion Bio made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #4422 holding.
  • Geode Capital Management first reported a position in Valion Bio in Q4 2023 and has held it in 7 quarters since.
  • Geode Capital Management's Valion Bio position peaked at $77.8K in Q1 2026.
  • 11 funds tracked by Wall St. Rank held Valion Bio as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.